{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:45:22Z","timestamp":1787496322861,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jconrel.2022.07.030","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T05:28:14Z","timestamp":1659331694000},"page":"756-764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["In-silico approach as a tool for selection of excipients for safer amphotericin B nanoformulations"],"prefix":"10.1016","volume":"349","author":[{"given":"Pooja A.","family":"Todke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma V.","family":"Devarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.07.030_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of amphotericin B: an overview of the main antifungal agent used to treat invasive fungal infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: recommendations, latest advances, and perspectives","volume":"30","author":"Brunet","year":"2020","journal-title":"J. Mycol. Med."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0015","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.36.10.2310","article-title":"Effects of the aggregation state of amphotericin B on its toxicity to mice","volume":"36","author":"Barwicz","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.05.013","article-title":"Effect of aggregation state on the toxicity of different amphotericin B preparations","volume":"361","author":"Espada","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0025","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.36.11.2518","article-title":"Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes","volume":"36","author":"Legrand","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0030","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0006-3495(02)75326-5","article-title":"Ion channel behavior of amphotericin B in sterol-free and cholesterol-or ergosterol-containing supported phosphatidylcholine bilayer model membranes investigated by electrochemistry and spectroscopy","volume":"83","author":"Huang","year":"2002","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0005-2736(93)90246-V","article-title":"Temperature effects on the aggregation state and activity of amphotericin B","volume":"1152","author":"Lambing","year":"1993","journal-title":"BBA-Biomembr."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0040","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.colsurfb.2013.01.041","article-title":"Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B\u2013miltefosine-loaded nanocochleates","volume":"106","author":"Pham","year":"2013","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2022.07.030_bb0045","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.41.11.2345","article-title":"Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index","volume":"41","author":"Gaboriau","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0050","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2174\/1381612822666151209151719","article-title":"Super aggregated form of amphotericin B: a novel way to increase its therapeutic index","volume":"22","author":"Zia","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0055","first-page":"4733","article-title":"NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency","volume":"8","author":"Burgess","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.07.030_bb0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/2211738504666160301233754","article-title":"Pharmacokinetics and renal toxicity of monomeric amphotericin B in rats after a multiple dose regimen","volume":"4","author":"Yeon Kang","year":"2016","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0065","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/1520-6017(200012)89:12<1589::AID-JPS10>3.0.CO;2-6","article-title":"The effect of serum albumin on the aggregation state and toxicity of amphotericin B","volume":"89","author":"Aramwit","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-03264-1","article-title":"Alginate-amphotericin B nanocomplexes covered by nanocrystals from bacterial cellulose: physico-chemical characterization and in vitro toxicity","volume":"11","author":"Soeiro","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejps.2018.01.017","article-title":"Amphotericin B-albumin conjugates: synthesis, toxicity and anti-fungal activity","volume":"115","author":"Gurudevan","year":"2018","journal-title":"Eur. J. Parenter. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.35.1.24","article-title":"Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose","volume":"35","author":"Gruda","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0085","first-page":"2629","article-title":"Structural characterization of the interaction of the polyene antibiotic amphotericin B with DODAB bicelles and vesicles","volume":"2011","author":"Oliveira","year":"1808","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0090","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2005.11.031","article-title":"Encapsulation of amphotericin B in poly (ethylene glycol)-block-poly (\u025b-caprolactone-co-trimethylenecarbonate) polymeric micelles","volume":"309","author":"Vandermeulen","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0095","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bm0257614","article-title":"Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(lamino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity","volume":"4","author":"Adams","year":"2003","journal-title":"Biomacromolecules."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.actbio.2016.09.036","article-title":"Biodegradable functional polycarbonate micelles for controlled release of amphotericin B","volume":"46","author":"Wang","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0105","first-page":"1","article-title":"Spectroscopic investigation of the aggregation state of amphotericin B during loading, freeze-drying, and reconstitution of polymeric micelles","volume":"7","author":"Adams","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0110","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.nano.2017.02.003","article-title":"Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations","volume":"13","author":"Dinh","year":"2017","journal-title":"Nanomed-Nanotechnol."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0115","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejps.2010.05.005","article-title":"Development of amphotericin B loaded polymersomes based on (PEG) 3-PLA co-polymers: factors affecting size and in vitro evaluation","volume":"40","author":"Jain","year":"2010","journal-title":"Eur. J. Parenter. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/polym11020270","article-title":"Noncovalent complexation of amphotericin B with poly (\u03b2-Amino Ester) derivates for treatment of C. neoformans infection","volume":"11","author":"Yu","year":"2019","journal-title":"Polymers."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0125","first-page":"354","article-title":"Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module","volume":"6","author":"Chaudhari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exppara.2018.07.017","article-title":"In-vitro and in-vivo antileishmanial activity of inexpensive amphotericin B formulations: heated amphotericin B and amphotericin B-loaded microemulsion","volume":"192","author":"Morais","year":"2018","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0135","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1208\/s12248-013-9474-6","article-title":"Comparative in silico\u2013in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin Gantrez nanoparticles","volume":"15","author":"D\u2019Souza","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0140","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00894-010-0811-8","article-title":"Molecular dynamics simulation of drug uptake by polymer","volume":"17","author":"Subashini","year":"2011","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0145","series-title":"In silico process for selecting protein formulation excipients. U.S. Patent Application 16\/081,102","author":"Insaidoo","year":"2019"},{"key":"10.1016\/j.jconrel.2022.07.030_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-02955-0","article-title":"In-silico screening of lipid-based drug delivery systems","volume":"37","author":"Brinkmann","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0155","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17425247.2016.1198770","article-title":"Rational excipient selection for co-amorphous formulations","volume":"14","author":"Korhonen","year":"2017","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0160","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.molpharmaceut.0c00313","article-title":"Enhancing safety and efficacy by altering the toxic aggregated state of amphotericin B in lipidic nanoformulations","volume":"17","author":"Das","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0165","author":"Chemspider server website"},{"issue":"2013","key":"10.1016\/j.jconrel.2022.07.030_bb0170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejps.2012.11.010","article-title":"A simple molecular modeling method for the characterization of polymeric drug carriers","volume":"48","author":"Mach\u00e1\u010dkov\u00e1","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.03.014","article-title":"Systematic approach to determination of permeation enhancer action efficacy and sites: molecular mechanism investigated by quantitative structure\u2212 activity relationship","volume":"322","author":"Yang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.07.030_bb0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jconrel.2019.11.033","article-title":"Dicarboxylic acid as a linker to improve the content of amorphous drug in drug-in-polymer film: effects of molecular mobility, electrical conductivity and intermolecular interactions","volume":"317","author":"Quan","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.07.030_bb0185","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1016\/j.xphs.2017.08.013","article-title":"Pharmacologically safe nanomicelles of amphotericin B with lipids: nuclear magnetic resonance and molecular docking approach","volume":"106","author":"Usman","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijpharm.2008.05.013","article-title":"Effect of aggregation state on the toxicity of different amphotericin B preparations","volume":"361","author":"Espada","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-11847-0","article-title":"Biomimetically engineered amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals","volume":"7","author":"Zia","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2015.11.034","article-title":"Lipoamino acid-based micelles as promising delivery vehicles for monomeric amphotericin B","volume":"497","author":"Serafim","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0205","first-page":"0914","article-title":"Amphotericin B: 50 years of chemistry and biochemistry","volume":"06","author":"Cereghetti","year":"2006","journal-title":"Synthesis."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0210","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1021\/jp510245n","article-title":"Self-association of amphotericin B: spontaneous formation of molecular structures responsible for the toxic side effects of the antibiotic","volume":"118","author":"Starzyk","year":"2014","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2022.07.030_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep19109","article-title":"Thermodynamics and kinetics of amphotericin B self-association in aqueous solution characterized in molecular detail","volume":"6","author":"Zieli\u0144ska","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bpc.2009.01.010","article-title":"Molecular modeling of amphotericin B\u2212ergosterol primary complex in water II","volume":"141","author":"Baran","year":"2009","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120511","article-title":"Innovative betulin nanosuspension exhibits enhanced anticancer activity in a triple negative breast cancer cell line and Zebrafish angiogenesis model","volume":"600","author":"John","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0230","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijpharm.2012.02.042","article-title":"Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability","volume":"429","author":"Kapse","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0235","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13346-014-0200-4","article-title":"Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand","volume":"4","author":"Joshi","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0240","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijpharm.2017.02.024","article-title":"In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: an in vivo proof of concept","volume":"521","author":"Jindal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/btm2.10112","article-title":"Polymeric curcumin nanoparticles by a facile in situ method for macrophage targeted delivery","volume":"4","author":"Jahagirdar","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13346-019-00670-x","article-title":"Shape mediated splenotropic delivery of buparvaquone loaded solid lipid nanoparticles","volume":"10","author":"Maithania","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120181","article-title":"Pre-clinical evaluation of an innovative oral nano-formulation of baicalein for modulation of radiation responses","volume":"595","author":"Joshi","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0260","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijpharm.2015.04.073","article-title":"Asymmetric lipid\u2013polymer particles (LIPOMER) by modified nanoprecipitation: role of non-solvent composition","volume":"489","author":"Jindal","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.030_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922004497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922004497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:33:32Z","timestamp":1759163612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922004497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":53,"alternative-id":["S0168365922004497"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.030","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-silico approach as a tool for selection of excipients for safer amphotericin B nanoformulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}